================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
SciClone Pharmaceuticals, Inc.
------------------------------------------------------
(Name of Issuer)
Common Stock, no par value
------------------------------------------------------
(Title of Class of Securities)
80862K104
------------------------------------------------------
(CUSIP Number)
November 9, 1999
------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act.
================================================================================
Page 1 of 4 Pages
<PAGE>
CUSIP No. 80862K104 13G Page 2 of 4 Pages
- --------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
Halifax Fund, L.P.
- --------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
(3) SEC USE ONLY
- --------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
- --------------------------------------------------------------------------------
(5) SOLE VOTING POWER
1,190,185
------------------------------------------------------
NUMBER OF (6) SHARED VOTING POWER
SHARES 0
BENEFICIALLY ------------------------------------------------------
OWNED BY (7) SOLE DISPOSITIVE POWER
EACH 1,190,185
REPORTING ------------------------------------------------------
PERSON WITH (8) SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,190,185
- --------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES [ ]
- --------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.6%
- --------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON:
00
- --------------------------------------------------------------------------------
<PAGE>
AMENDMENT NO. 1 TO SCHEDULE 13G
The Schedule 13G, dated December 30, 1998, of Halifax Fund, L.P. (the
"Reporting Person") is hereby amended as set forth below.
The purpose of this Amendment No. 1 to Schedule 13G is to update
information regarding Halifax Fund, L.P.'s holdings in securities of the issuer
as described herein. Except as specifically provided herein, this Amendment No.
1 to Schedule 13G does not modify any of the information previously reported in
the Schedule 13G, and should be read in conjunction with, and is qualified in
its entirety by reference to, the Schedule 13G.
Item 4 is hereby amended as set forth below:
Item 4. Ownership.
- ------- ---------
(a) Amount Beneficially Owned: 1,190,185
(b) Percent of Class: 4.6%
(c) Number of Shares to which such person has:
(i) Sole power to vote or direct
the vote: 1,190,185
(ii) Shared power to vote or direct
the vote: 0
(iii) Sole power to dispose or to direct
the deposition of: 1,190,185
(iv) Shared power to dispose or to
direct the disposition of: 0
Item 5 is hereby amended as set forth below:
Item 5. Ownership of Five Percent or Less of a Class.
- ------- ---------------------------------------------
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following [X].
Page 3 of 4 Pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
November 22, 1999
------------------------------
Date
Halifax Fund, L.P.
By: The Palladin Group, L.P.
Attorney-in-fact
By: Palladin Capital
Management, L.L.C.
General Partner
/s/ Robert L. Chender
------------------------------
Signature
Robert L. Chender
Duly Authorized Signatory
------------------------------
Name/Title
Page 4 of 4 Pages
